1. Home
  2. MDRR vs INTS Comparison

MDRR vs INTS Comparison

Compare MDRR & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MDRR

Medalist Diversified REIT Inc.

HOLD

Current Price

$11.41

Market Cap

16.3M

Sector

Real Estate

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$5.22

Market Cap

13.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDRR
INTS
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.3M
13.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MDRR
INTS
Price
$11.41
$5.22
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
1.2K
28.0K
Earning Date
03-02-2026
05-07-2026
Dividend Yield
2.43%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.55
$0.19
52 Week High
$14.52
$8.06

Technical Indicators

Market Signals
Indicator
MDRR
INTS
Relative Strength Index (RSI) 50.59 44.02
Support Level $11.00 $5.04
Resistance Level $12.45 $8.06
Average True Range (ATR) 0.08 0.20
MACD 0.01 -0.01
Stochastic Oscillator 37.28 50.01

Price Performance

Historical Comparison
MDRR
INTS

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: